Amgen (NASDAQ: AMGN) and AstraZeneca announced positive top-line results from the phase 3 CROSSING trial of Tezspire (tezepelumab-ekko) in patients ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE